Durlobactam Sodium is the monosodium salt of Durlobactam. It has a role as a potent beta-lactamase inhibitor and an antibacterial compound. It is an analog of avibactam. Durlobactam is member of the diazabicyclooctane (DBO) class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases. It is often used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter. It was discovered using structure-based compound design study.
Durlobactam Sodium is soluble in water.
| Mechanism of Action | Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. When formulated in combination with sulbactam, it protects sulbactam from degradation by certain serine-beta-lactamases. The covalent bond between durlobactam and β-lactamase is reversible via its recyclization by the sulfated amine group on Durlobactam to be exchanged from one enzyme molecule to another, called acylation exchange. |
| Spectrum |
Durlobactam is a next generation β-lactamase inhibitor with an extended spectrum of activity compared to other commercially available β-lactamase inhibitors. Sulbactam-durlobactam is currently active against Acinectobacter. It was designed to improve activity against Gram-negative bacteria. |
| Microbiology Applications |
Durlobactam Sodium can be used in studies about drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Diazabicyclooctanes (DBOs) are broad-spectrum β-lactamase inhibitors that inhibit certain peptidoglycan transpeptidases involved in mycobacterial cell wall synthesis. We evaluated Durlobactam as an inhibitor of BlaC, the Mtb β-lactamase, and multiple Mtb peptidoglycan transpeptidases (ref). This work supports further exploration of novel β-lactamase inhibitors that target BlaC and Mtb peptidoglycan transpeptidases. durlobactam was a potent and efficient DBO inhibitor of BlaC and similar to clavulanate, but it had a lower turnover number than clavulanate. Susceptibility testing was conducted on 11 Mycobacterium tuberculosis isolates with Durlobactam (in addition to and amoxicillin, ceftriaxone, meropenem, imipenem, clavulanate). Durlobactam had a minimum inhibitory concentration (MIC) range of 0.5–16 μg/mL, similar to the ranges for meropenem (1–32 μg/mL) and imipenem (0.5–64 μg/mL). Researchers evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against Mycobacterium abscessus (Mab) and explored the underlying mechanisms. Durlobactam alone showed ~2 log10 reduction, and when combined with imipenem , durlobactam achieved near-eradication of Mab. This combination leveraged a dual synergy mechanism that targeted multiple L,D-transpeptidases and penicillin binding proteins. Further dynamic in vitro studies are needed to validate these findings (Shin et al, 2025). |
| Molecular Formula |
C8H10N3NaO6S |
| References |
Nantango, M (2024) Durlobactam, a diazabicyclooctane β-Lactamase inhibitor, inhibits BlaC and peptidoglycan transpeptidases of Mycobacterium tuberculosis. ACS Infect. Dis. 10(5):1767-1779 Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA (2021) Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with Sulbactam. Front Microbiol. 12:709974 PMID 34349751 Shin E et al (2025) Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrob. Agents Chemother. 69:e01174-24 |
